Technique Segment Analysis: Low Dose Rate (LDR) (Largest Segment) vs High Dose Rate (HDR) (Fastest-Growing Segment)

The brachytherapy devices market was led by the low dose rate (LDR) technique, which accounted for 75.36% of the market share in 2026. Its strong position is supported by its long-established clinical use, proven effectiveness across multiple cancer indications, and ability to deliver continuous radiation directly to the treatment site while minimizing exposure to surrounding healthy tissues. The widespread adoption of permanent implant procedures and the availability of well-established treatment protocols have further reinforced the preference for LDR brachytherapy in routine clinical practice.

The high dose rate (HDR) technique is expected to witness the fastest growth over the forecast period owing to its ability to deliver precise radiation doses within shorter treatment sessions while offering greater flexibility in treatment planning. Growing demand for minimally invasive cancer therapies, advances in imaging-guided treatment delivery, and increasing emphasis on patient convenience are encouraging broader adoption of HDR systems across oncology centers.

Product Type Segment Analysis: Seeds (Largest Segment) vs Electronic Brachytherapy (Fastest-Growing Segment)

Seeds represented the largest product type, capturing 62.21% of the market share in 2026. Radioactive seeds remain widely utilized because they provide targeted, localized radiation with high treatment accuracy and have demonstrated reliable outcomes in cancers requiring permanent implantation. Their established clinical acceptance, procedural familiarity among healthcare professionals, and compatibility with standard brachytherapy techniques continue to support their dominant market position.

The brachytherapy devices market is anticipated to experience the fastest growth in the electronic brachytherapy segment as healthcare providers increasingly seek radiation delivery systems that eliminate the need for radioactive isotope handling. Technological advancements, simplified treatment workflows, and expanding adoption of compact radiation systems capable of supporting outpatient procedures are contributing to the rapid expansion of this segment.

End-use Segment Analysis: Hospitals (Largest Segment) vs Specialty Clinics (Fastest-Growing Segment)

Hospitals accounted for 60.84% of the market share in 2026, reflecting their comprehensive oncology infrastructure, access to multidisciplinary cancer care teams, and availability of advanced imaging and radiation treatment technologies. Their ability to manage complex cases, provide integrated diagnostic and therapeutic services, and perform specialized brachytherapy procedures has maintained their leadership within the end-use segment.

Specialty clinics are projected to register the fastest growth over the forecast period. Increasing patient preference for specialized cancer treatment centers, shorter waiting times, and personalized oncology services is driving greater utilization of these facilities. Expanding investments in dedicated radiation therapy infrastructure and growing availability of advanced brachytherapy technologies are further supporting the development of specialty clinics.